- 2023.03.31
As a global innovative biotech company, we are passionate about creating transformational therapies through innovation to address unmet medical needs in oncology for patients worldwide.
Lemzoparlimab CD47
Uliledlimab CD73
Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB
mRNA, Probody
AI Design, Alphabody
Press Releases
2023.03.20
The Company announced date of reporting financial results for year 2022.
2023.03.13
I-Mab today issued a statement on the recent developments of the SVB.
2023.03.07
I-Mab has been granted “A” rating by Morgan Stanley Capital International ESG.
Events
Since its establishment, I-Mab has been focusing on developing innovative biologics in immuno-oncology. Through three waves of innovation, we have built a globally competitive pipeline. Our global clinical development and strategic partnership model fuels our sustainable innovation and growth, with proven track record of validation and recognition.
Jingwu Zang
Founder and Chairman